[Goose]

https://marlin-prod.literatumonline.com/...326611.pdf


It explains how some individuals came to receive a half-dose for their initial dose:


<snip>

One thing that I had been looking for is how well the vaccine prevents severe disease:

More than 21 days after their first dose, ten participants were  hospitalised  due  to  COVID-19  (defined  as  WHO  clinical  progression  score  ≥4),  two  of  whom  were  assessed  as  having  severe  COVID-19  (WHO  score  ≥6),  including one fatal case. All ten cases were in the control group (table 5).

So, with limited data (only 10 events), it does look like both the standard and low dose vaccines were effective in preventing serious COVID-19.


BC

So overall pretty good news. Seems they are going for the EUA with the data they have and do not think they will need another trial to get it. As I read the paper, efficacy was a little "muddled", but ranged from 62.5% to 90%, depending on the protocol. Not perfect, but useful. The total lack of severe disease in the treated group is encouraging even with small N.

[Goose]

https://marlin-prod.literatumonline.com/...326611.pdf


It explains how some individuals came to receive a half-dose for their initial dose:


<snip>

One thing that I had been looking for is how well the vaccine prevents severe disease:

More than 21 days after their first dose, ten participants were  hospitalised  due  to  COVID-19  (defined  as  WHO  clinical  progression  score  ≥4),  two  of  whom  were  assessed  as  having  severe  COVID-19  (WHO  score  ≥6),  including one fatal case. All ten cases were in the control group (table 5).

So, with limited data (only 10 events), it does look like both the standard and low dose vaccines were effective in preventing serious COVID-19.


BC

So overall pretty good news. Seems they are going for the EUA with the data they have and do not think they will need another trial to get it. As I read the paper, efficacy was a little "muddled", but ranged from 62.5% to 90%, depending on the protocol. Not perfect, but useful. The total lack of severe disease in the treated group is encouraging even with small N.